Tiffany A. Traina, MD, a medical oncologist at Weill Cornell Medicine, discusses the current treatment landscape for patients with triple-negative breast cancer.
Tiffany A. Traina, MD, a medical oncologist at Weill Cornell Medicine, discusses the current treatment landscape for patients with triple-negative breast cancer (TNBC).
Traina says it is very encouraging right now for patients with TNBC, while there is an increasing recognition of subsets within the disease. With the recent FDA approval of olaparib (Lynparza) and positive results from a phase III trial in patients with BRCA mutations, Traina says it is more evident than ever that there are many germline mutations in TNBC that must be recognized for successful treatment of patients with TNBC.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More